Revolution Medicines Inc

Discover how Revolution Medicines COO Margaret Horn’s 10(b)(5)(1) trades reveal insider confidence, strategic liquidity, and pipeline optimism in the high‑volatility oncology sector.

Revolution Medicines insider trades show disciplined liquidity management, aligning with an aggressive Phase III pipeline and strategic pricing power for future growth.